Wang Y, et al. - Considering the possibility that several kinds of breast cancer stem-like cells could be (CSC) responsible for treatment failure in breast cancer that they could be identified by different markers, researchers assessed the correlation of CXCR2 to breast CSC as it is involved in breast cancer metastasis, treatment resistance, and recurrence and has positive cross-talk with known breast CSC protein markers. They assessed the expression of CXCR2 with immunohistochemistry in breast cancer tissues from 37 patients and discovered that level of CXCR2 was significantly lower in triple-negative breast cancer (TNBC) compared with non-TNBC. Outcomes suggest that for TNBC alone, CXCR2 is an acceptable and newly discovered CSC marker.